Latest Breaking News On - Professor ramin tadayoni - Page 1 : comparemela.com

OCS-01’s positive results in Stage 1 of the Phase 3 DIAMOND trial for diabetic macular edema (DME) were presented as a late-breaking abstract showing that the trial met primary and secondary endpoints with robust statistical significanceOn track to commence Stage 2 of the DIAMOND program with two parallel global Phase 3 trialsIf approved, OCS-01 has the potential to become the first topical eye drop for the treatment of DME ZUG, Switzerland and BOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) Oculis Ho

France generalUnited statesNoord hollandSylvia cheungCorey davisRamin tadayoniAdolphe de rothschild foundationOculis holding ag nasdaqDepartment head at lariboisiProfessor ramin tadayoniBest corrected visual acuityParis citDepartment headSaint louisOculi scientific advisory boardChief executive officer